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INTRODUCTION
Regional body fat distribution has an important influence
on metabolic and cardiovascular risk factors. Many prospec-
tive studies have shown that increased abdominal fat accu-
mulation is an independent risk factor for coronary artery
disease, hypertension, stroke, and type 2 diabetes mellitus
(T2DM) (1-3). 
In 1988, Reaven described what has now become known
as insulin resistance syndrome (also called metabolic syn-
drome) (4). Since then, the definitions have been expanded
to include a cluster of interrelated cardiovascular risk factors
including central adiposity, hypertension, dyslipidemia, and
disturbances of fibrinolysis, with abnormalities of insulin
metabolism at the core.
Many people with metabolic diseases, such as DM, hyper-
tension, and atherosclerosis, have normal weights in the clini-
cal setting. Ruderman et al. stated that there are many non-
obese people with a condition called metabolic obesity, which
indicates a higher risk of developing metabolic diseases because
of insulin resistance due to abdominal obesity (5). For this
reason, it was recommended that these individuals control
their diets and exercise during the early stage of abdominal
obesity to alleviate visceral obesity and prevent subsequent
development of metabolic diseases. Therefore, it is implied
that overall obesity determined by body mass index (BMI)
cannot be the sole indicator of increased risk for metabolic
disorders, and has limitations in evaluating insulin resistance. 
Many studies support the idea that fat accumulated in the
viscera, unlike subcutaneous fat, has an important role in
metabolic activity (6). In fact, it has been proven that visceral
fat leads to insulin resistance and hyperinsulinemia, and is
closely related with hyperlipidemia and hypertension, which
promote atherosclerosis. This suggests that visceral obesity
is equivalent to metabolic obesity (2, 7). 
Patients with T2DM are at high risk for coronary heart
disease, cerebrovascular disease or stroke, and peripheral
vascular disease. Their risk for these disorders is 2 to 6 fold
higher than that in persons without diabetes. These macrovas-
cular diseases are common causes of morbidity and mortali-
ty among people with diabetes. In recent years, non-inva-
sive methods have been developed to measure the intima-
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Association of Abdominal Obesity with Atherosclerosis in Type 2 
Diabetes Mellitus (T2DM) in Korea
The aim of this study was to investigate the relationship between obesity, insulin
resistance and atherosclerosis in type 2 diabetes mellitus (T2DM) patients. Total
530 patients with T2DM were included. To evaluate the severity of  atherosclero-
sis, we measured the coronary artery calcification (CAC) score, intima-media thick-
ness (IMT) of the common carotid artery, and the ankle-brachial pressure index
(ABPI). Subjects were classified according to body mass index (BMI), a marker of
general obesity, and waist-to-hip ratio (WHR), a marker of regional obesity. The
insulin sensitivity index (ISI) was measured by the short insulin tolerance test. All
subjects were classified into four groups, according to BMI: the under-weight group,
the normal-weight (NW) group, the over-weight (OW) group, and the obese (OB)
group. WHR and systolic blood pressure, triglycerides (TG), HDL-cholesterol (HDL-
C), free fatty acids (FFA), fibrinogen, and fasting c-peptide levels were significantly
different between BMI groups. TG, HDL-C, FFA, fibrinogen and ISI were signifi-
cantly different between patients with and without abdominal obesity. In the OW
group as well as in the NW group, carotid IMT, ABPI and CAC score were signifi-
cantly different between patients with and without abdominal obesity. This study
indicates that abdominal obesity was associated with  atherosclerosis in T2DM
patients.  
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media thickness (IMT) of the carotid artery, coronary artery
calcification (CAC) and ankle-brachial pressure index (ABPI)
as an index for atherosclerosis (8, 9).
Thus, the aim of this study was to investigate whether
general and abdominal obesities were associated with athero-
sclerosis in Korean T2DM patients.
MATERIALS AND METHODS
Subjects
This study was comprised of 530 patients (male:female=
319:211, mean age 56 yr) with T2DM at our affiliated hos-
pitals and clinic from December 2002 to February 2005. The
study protocol adopted was approved by the Yonsei Univer-
sity College of Medicine Ethical Committee and informed
consent was obtained from all patients. The subjects were
classified into four groups, according to BMI: 1) the under-
weight (UW) group (BMI <18.5 kg/m2), 2) the normal-
weight (NW) group (18.5-22.9 kg/m2), 3) the over-weight
(OW) group (23-24.9 kg/m2), and 4) the obese (OB) group
(25 or more kg/m2). 
Methods
Hypertension was defined as systolic blood pressure (SBP)
≥140 mmHg or diastolic blood pressure (DBP) ≥90
mmHg, and/or reported treatment with antihypertensive
medications in the past 2 weeks. SBP and DBP values were
classified as stage 1 hypertension criteria by Joint National
Committee (JNC) 7 report 2003.
Measurement of anthropometric parameters
Body weight and height were measured in the morning,
with participants wearing light clothing. BMI was calculat-
ed as body weight in kilograms divided by height in meters
squared (kg/m2). Waist circumference was measured with a
soft tape, midway between lowest rib and iliac crest, with
standing position. Hip circumference was measured over
the widest part of the gluteal region, and waist-to-hip ratio
(WHR) was calculated accordingly. Body fat percentage
was evaluated by dual-energy radiography absorptiometry
(QDR 1500, Hologic, MA, U.S.A.).
Measurement of insulin resistance 
To evaluate insulin resistance in all individuals, a short
insulin tolerance test was performed and assessed by Kitt.
With the subject at rest, 0.1 U per kg of body weight of a
100 times diluted short-acting human insulin (Humulin-
R, Eli Lilly, IN, U.S.A.) was administered via the vein, and
a blood sample was obtained from the opposite vein 0, 3, 6,
9, 12, and 15 min. Each blood sample was immediately cen-
trifuged and its glucose concentration determined. The insulin
sensitivity index (ISI, %/min) was derived by linear regres-
sion from the rate of fall of the log glucose value between 3
and 15 min. T1/2 was calculated when the baseline blood glu-
cose level reached 50% of its initial value, and the ISI was
calculated from the equation: 
ISI=Kitt (rate constant for plasma glucose disappearance)=
0.693/t1/2*100 (%/min)
Measurement of biochemical profiles
Blood was sampled from all of the subjects after fasting
for more than 10 hr. Plasma glucose concentrations were
measured with a standard glucose oxidase reference method
(747 automatic analyzer, Hitachi, Tokyo, Japan). HbA1c
was analyzed using high performance liquid chromatogra-
phy (Variant II, Bio-Rad, CA, U.S.A.). Serum C-peptide
concentrations were determined by an enzyme chemilumi-
nescence immunoassay (ECIA, DPC, LA, U.S.A.). 
The serum total cholesterol and HDL-cholesterol were
measured using a direct enzymatic method (747 automatic
analyzer, Hitachi). Serum triglyceride (TG) levels were mea-
sured by an enzymatic colorimetric method (747 automatic
analyzer, Hitachi), and LDL-cholesterol was calculated using
the Fridewald’s equation. Serum free fatty acid (FFA) concen-
trations were determined by colorimetry. Fibrinogen was
measured in citrated plasma by a modified clot-rate assay
(Pacific Hemostasis Assay Set, Humlersville, NC, U.S.A.).
Measurement of coronary artery calcification 
The amount of calcium deposition in the coronary artery
was measured using electron beam computed tomography
(EBT) (Imatron Ultrafast CT, General Electric, WI, U.S.A.).
In order to get an EBT image during the diastolic phase, 3
mm thick imaging slices of the heart were obtained from
the lower margin of the main pulmonary artery to the dia-
phragm, after gating of the Electrocardiogram according to
80% of the R-R interval. The score of calcification in the
right and left coronary artery was measured. The resultant
score of CAC was calculated as the density/pixel (0.5 mm2)
using the method of Agatston et al. (10). 
Measurement of intima-media thickness 
IMT was measured using high-resolution B-mode ultra-
sound (Toshiba SSA 270A, Tokyo, Japan) with an electric
linear transducer (7.5 MHz) according to the method of
Pignoli et al. (11). All measurements were blindly evaluat-
ed by the same experienced physician who had no informa-
tion about the patients. Plaque in the common carotid artery
was defined by high echogenicity with a postechogenic shad-
ow or more than 1.3 mm of IMT according to the Multicen-
ter Isradipine Diuretic Atherosclerosis Study (MIDAS) (12). 
Measurement of ankle-brachial pressure index 
Brachial blood pressure and ankle blood pressure were
measured using Plethysmography (Modulab, Life Science,CT, U.S.A.). The ankle-brachial pressure index (ABPI) was
calculated automatically.
Measurement of regional fat distribution by computed 
tomography 
The abdominal adipose tissue area and midthigh muscle
area were quantified using computed tomography (Tomoscan
350, Phillips, NJ, U.S.A.). Adipose tissue was defined as
having a density of -150 to -50 Hounsfield units (13), and
was divided into visceral fat tissue (the inner portion) and
subcutaneous fat tissue (the outer portion), according to its
position relative to the peritoneal membrane. The visceral
fat area/subcutaneous fat area (VSR) was calculated as the
ratio of visceral fat area to subcutaneous fat area. Measure-
ments of skeletal muscle area (Hounsfield units, -49 to 100)
from the middle of the femur yielded visceral fat area/thigh
muscle area ratios (VMRs).
Statistical analysis
Descriptive statistics are presented as mean values±SD.
Comparisons between the groups were tested using one way
Analysis of Variance (ANOVA) or independent sample t-
tests or chi-Square tests, as appropriate. We used the linear-
by-linear association method to analyze the effect of BMI on
variable metabolic parameters. Statistical analyses were con-
ducted using SPSS for Windows, version 11.0 (SPSS Inc.,
Chicago, IL, U.S.A.), and p<0.05 was set as the level of sig-
nificance. 
RESULTS
Clinical and biochemical characteristics according to BMI 
Among the 530 patients, 47 patients (8.9%), 184 patients
(34.7%), 154 patients (27.4%), and 154 patients (29.1%)
belonged to the UW, NW, OW, and OB groups, respective-
ly. There was no significant difference in age, duration of
DM, SBP, DBP, or HbA1c levels between the different BMI
groups (Table 1). Additionally, WHR and body fat content
increased significantly as BMI increased (0.82±0.11, 0.89
±0.16, 0.93±0.10, 0.97±0.16, for WHR, respectively,
p=0.021 and 21.2±5.2%, 23.2±5.4%, 27.4±4.8%, 31.5
±5.5%, for body fat content, respectively, p=0.027). 
There were no differences in the percentage of patients
with a history of taking antihypertensive drugs, smoking
history, or presence of microvascular (nephropathy, neuropa-
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UW NW OW OB
Number 47 184 145 154
Sex (M:F) 27:20 113:71 89:56 90:64
Age (yr) 53.2±11.8 56.4±14.3 57.3±10.7 57.4±12.4
BMI (kg/m
2) 17.2±1.1 20.2±1.4* 24.2±0.7
� ,� 27.3±1.9
� ,‖,¶
WHR 0.82±0.11 0.89±0.16* 0.93±0.10
� ,� 0.97±0.16
� ,‖
Body fat percent (%) 21.2±5.2 23.2±5.4* 27.4±4.8
� ,� 31.5±5.5
� ,‖,¶
DM duration (yr) 11.4±7.2 10.8±5.8 11.1±6.6 10.5±7.0
Antihypertensive medication (%) 6/47 (12.8) 23/184 (12.5) 19/145 (13.1) 27/154 (17.5)
Smoking (%) 10/47 (21.3) 42/184 (22.8) 35/145 (24.1) 34/154 (22.0)
Nephropathy (%) 16/47 (34.0) 66/184 (35.9) 49/145 (33.8) 56/154 (36.4)
Neuropathy (%) 28/47 (59.6) 106/184 (57.6) 91/145 (62.8) 98/154 (63.6)
Retinopathy (%) 18/47 (38.3) 68/184 (37.0) 53/145 (36.6) 62/154 (40.3)
Prevalence of CHD (%) 2/47 (4.3) 7/184 (3.8) 7/145 (5.3) 7/154 (4.5)
SBP (mmHg) 135.2±21.1 135.8±19.8 136.4±17.1
� ,� 140.6±22.8
� ,‖,¶
DBP (mmHg) 81.1±10.8 85.6±10.4 87.6±9.4 88.8±10.8
TC (mM/L) 4.86±0.88 5.04±1.12 5.36±0.64 5.20±0.84
TG (mM/L) 1.64±0.58 1.96±0.81* 1.97±0.67
� 1.97±0.72
�
HDL-C (mM/L) 1.28±0.27 1.13±0.30* 1.10±0.28
� 1.10±0.32
�
HbA1c (%) 10.0±2.3 9.2±3.2 9.4±1.1 9.2±4.1
FFA (nM/L) 2.55±0.93 2.21±0.72* 2.35±0.65
� ,� 2.64±1.25
� ,‖,¶
Fibrinogen (g/L) 4.14±0.83 4.01±0.92* 4.10±0.68
� ,� 4.18±0.87
� ,‖,¶
24-hr albumin (g) 0.404±0.189 0.431±0.244 0.455±0.197 0.463±0.191
C-peptide (μ g/L) 1.45±1.02 1.49±1.91 1.54±1.62 1.80±1.87
� ,‖,¶
ISI (%/min) 2.45±2.10 2.37±2.14 2.23±2.03 1.96±1.98
Insulin resistance (%) 13/47 (27.7) 103/184 (56.0)* 94/145 (64.8)
� ,� 106/154 (68.8)
� ,‖,¶
Table 1. The clinical and biochemical characteristics of patients according to BMI
Values are mean±SD. UW, under weight; NW, normal weight; OW, over weight; OB, obese; BMI, body mass index; WHR, waist-to-hip ratio; DM,
diabetes mellitus; CHD, coronary heart disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total cholesterol; TG, triglyceride;
HDL-C, HDL-cholesterol; FFA, free fatty acid; ISI, insulin sensitivity index. 
*UW vs. NW, p<0.05; 
� UW vs. OW, p<0.05; 
� UW vs. OB, p<0.05; 
�NW vs. OW, p<0.05; 
‖NW vs. OB, p<0.05; 
¶OW vs. OB, p<0.05. thy, retinopathy) or macrovascular (atherosclerosis) compli-
cations of DM among each group. SBP increased significantly
as BMI increased (p=0.044), although DBP did not differ
significantly between the groups. Total cholesterol level was
not different between the groups. However, serum TG level
was significantly lower in the UW group. Additionally, HDL-
cholesterol was considerably higher in the UW group com-
pared with the remaining groups. Significant differences in
FFA levels were observed when patients were categorized
into groups depending on their BMI (p=0.026). Moreover,
there were considerable differences in serum fibrinogen lev-
els among groups (p=0.037). There was no difference in 24-
hr urinary albumin excretion between the groups. Significant
differences were seen in fasting serum C-peptide levels bet-
ween OB group and the others, but no difference was found
between the UW, NW and the OW group. There was no
notable difference in insulin resistance (ISI) between groups,
with ISI values of 2.45±2.10, 2.31±2.11, 1.97±1.90,
and 1.89±2.22%/min, respectively. In addition, if an ISI
of 2.5%/min is taken to be the standard value for insulin
resistance, insulin resistance was observed more frequently
in patients with higher BMIs (p=0.042) (Table 1).
We compared the visceral fat area, subcutaneous fat area, and
midthigh muscle area for 80 subjects that were matched for
sex, age, and BMI, by separating the NW or OW subjects
according to their insulin sensitivity. The insulin resistant
subgroup (ISI<2.5%/min, N=39) had a larger visceral fat area
(p<0.0001), a larger subcutaneous fat area (p=0.05), and less
midthigh muscle area (p=0.027) than the non-insulin resistant
subgroup (ISI ≥2.5%/min, N=41). Therefore, the patients
with insulin resistance had a higher VSR (p=0.040) and VMR
(p<0.0001) than patients without insulin resistance (Table 2). 
Clinical and biochemical characteristics according to
WHR as an estimate of abdominal obesity 
In the NW and OW group, the male subjects had 0.95
of the median value of WHR, whereas female subjects had
0.91 of the median value. Subjects with abdominal obesity,
according to the median value of their WHR, were grouped
together.  There was no difference in age, BMI or the dura-
tion of diabetes between these groups in either male or female
subjects. However, the group with higher WHR had a high-
er body fat percentage in both male subjects (p=0.004) and
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IR group
(N=39)
Non-IR group
(N=41)
p value
Sex (M:F) 23:16 24:17 0.968
Age (yr) 57.3±12.1 55.4±12.1 0.485
BMI (kg/m
2) 22.2±1.1 22.3±1.3 0.712
WHR 0.95±0.05 0.91±0.05 0.001
Body fat percent (%) 28.1±5.5 24.2±5.2 0.002
DM duration (yr) 11.1±6.3 10.8±6.5 0.835
Visceral fat area (cm
2) 152.0±60.7 96.5±28.5 <0.0001
SQ fat area (cm
2) 184.2±84.5 126.9±59.7 0.001
Thigh muscle area (cm
2) 99.7±28.6 114.6±30.6 0.027
VSR 0.83±0.16 0.76±0.14 0.040
VMR 1.52±0.38 0.84±0.24 <0.0001
Table 2. Comparison of abdominal fat and thigh muscle areas
by CT scan between the insulin resistant (IR) group and non-
insulin resistant (non-IR) group, according to insulin sensitivity
index
Values are mean±SD.
BMI, body mass index; WHR, waist-to-hip ratio; DM, diabetes mellitus;
SQ, subcutaneous; VSR, visceral fat area/subcutaneous fat area ratio;
VMR, visceral fat area/thigh muscle area.
Men (N=115)
<0.95 p value ≥0.95
Women (N=100)
<0.91 p value ≥0.91
Number 75 40 61 39
Age (yr) 55.2±11.8 56.2±12.1 0.669 58.3±11.1 57.4±10.2 0.684
BMI (kg/m
2) 22.8±1.1 22.4±1.2 0.075 22.7±1.3 22.4±1.1 0.236
Fat (%) 24.2±5.2 21.1±5.7 0.004 28.2±5.6 25.3±5.2 0.011
DM duration (yr) 10.3±7.2 10.9±6.2 0.656 11.1±7.2 10.2±6.4 0.526
SBP (mmHg) 136.2±21.1 133.1±18.1 0.433 138.9±23.2 132.2±18.2 0.130
DBP (mmHg) 85.1±10.8 83.5±10.1 0.441 86.1±11.2 85.1±10.2 0.653
Hypertention (%) 49/75 (65.3) 16/40 (40.0) 0.009 38/61 (62.3) 13/39 (33.3) 0.005
TC (mM/L) 4.98±0.88 4.97±1.08 0.957 5.28±0.81 5.25±0.81 0.857
TG (mM/L) 2.06±0.58 1.85±0.42 0.028 2.05±0.64 1.77±0.66 0.039
HDL-C (mM/L) 1.06±0.26 1.67±0.29 <0.0001 1.10±0.30 1.26±0.34 0.015
HbA1c (%) 9.0±2.3 9.1±2.1 0.819 9.1±1.0 9.0±2.2 0.791
FFA (nM/L) 2.55±0.73 2.27±0.64 0.043 2.69±0.92 2.35±0.75 0.046
Fibrinogen (g/L) 4.18±0.83 3.53±0.81 0.000 4.21±0.76 3.89±0.81 0.048
ISI (%/min) 2.01±1.84 2.78±1.95 0.039 2.02±1.57 2.68±1.68 0.049
Table 3. The comparison of abdominal obesity according to WHR in normal and over-weight DM patients
Values are mean±SD.
BMI, body mass index; WHR, waist-to-hip ratio; DM, diabetes mellitus; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total choles-
terol; TG, triglyceride; HDL-C, HDL-cholesterol; FFA, free fatty acid; ISI, insulin sensitivity index. female subjects (p=0.011). Both SBP and DBP were not sig-
nificantly different between the two groups, but subjects
with higher WHR had a higher prevalence of hypertension
(for male, p=0.009 and for female, p<0.05) There were no
significant differences in total cholesterol between the two
groups. However, serum TG level was higher in both male
and female patients with higher WHR than in patients with
lower WHR (p=0.028 in males; p=0.039 in females). More-
over, HDL-cholesterol levels were significantly lower in both
male and female patients with higher WHR (p<0.0001 in
males; p=0.015 in females). No differences were observed in
serum HbA1c levels between the two groups, but serum FFA
levels were considerably increased in male and female patients
with higher WHR (p=0.043 in males; p=0.046 in females).
Serum fibrinogen concentrations were also higher in male
and females patients with higher WHR (p=0.000 in males;
p=0.048 in females). ISI was significantly lower in male and
female patients with higher WHR (2.01±1.84 vs. 2.78±
1.95%/min, p=0.039, in male patients; 2.02±1.57 vs. 2.68
±1.68%/min, p=0.049, in female patients) (Table 3). 
The degree of atherosclerosis according to WHR as an
estimate of abdominal obesity 
In the NW, OW and the OB groups, male subjects with
abdominal obesity had a greater IMT than those without
abdominal obesity (1.01±0.21 vs. 0.87±0.21 mm, p=
0.012; 1.04±0.31 vs. 0.92±0.24 mm, p=0.008; 1.08±
0.22 vs. 0.96±0.21 mm, p=0.006, respectively). However,
there were no differences in IMT between the NW, OW, and
OB groups (Fig. 1). Similarly, female subjects with abdomi-
nal obesity had a greater IMT in NW, OW, and OB group
(0.94±0.17 vs. 0.84±0.16 mm, p=0.0025; 1.00±0.33 vs.
0.86±0.34 mm, p=0.007; 1.05±0.22 vs. 0.90±0.17 mm,
p<0.001, respectively). However, there were no significant
differences between the NW, OW, and OB groups (Fig. 1). 
In terms of ABPI, male subjects with abdominal obesity
had a lower level of atherosclerosis than those without abdom-
inal obesity in NW, OW, and OB group (1.01±0.08 vs.
1.11±0.07, p=0.004; 1.01±0.09 vs. 1.06±0.05, p=0.024;
1.03±0.05 vs. 1.10±0.05, p<0.001, respectively). How-
ever, there was no difference in atherosclerosis in male sub-
jects between each groups (Fig. 2). Similarly, female subjects
had a lower level of atherosclerosis in the NW, OW, and OB
group (1.02±0.07 vs. 1.07±0.08, p=0.008; 0.98±0.06
vs. 1.04±0.07, p=0.002; 0.99±0.06 vs. 1.06±0.07, p<
0.001, respectively) but no difference was found between
each groups (Fig. 2). 
Lower CAC scores, as measured by EBT, were found in
subjects with abdominal obesity than in those without abdom-
inal obesity, in the NW group (2.47±2.16 vs. 1.99±1.86
logHU, p<0.001), the OW group (3.53±2.39 vs. 2.10±
2.21 logHU, p<0.001), and the OB group (2.45±2.25 vs.
2.12±2.35 logHU, p<0.001). However, there was no dif-
ference in CAC scores between the groups (Fig. 3). 
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DISCUSSION
When compared to Caucasian T2DM patients, Korean
patients with T2DM have a lower prevalence of obesity accord-
ing to BMI (14). In this study, more than 70% of the sub-
jects had a BMI within or below the normal range. Howev-
er, 60% of the group with a normal BMI (20-25 kg/m2) had
insulin resistance. When classified according to insulin resis-
tance, there was no difference in BMI between the subjects
with and without insulin resistance. This may be a charac-
teristic of Korean T2DM patients. Huh (15) measured the
fasting insulin level in Koreans within a range of fasting plas-
ma glucose from 4.44 to 11.10 mM/L, and found that over-
weight subjects had a peak level of insulin of 100.5 pM/L at
7.77 mM/L of fasting blood glucose, and normal weight sub-
jects had their peak level of insulin of 57.4 pM/L at 5.83 mM/
L of fasting blood glucose. These Korean insulin levels are
half as much as those reported for Caucasians (16, 17). There-
fore, it has been suggested that Koreans are at increased risk
of developing diabetes despite their mild degree of insulin
resistance, possibly due to decreased insulin secretion capac-
ity of their β -cells, due to ethnic or environmental factors.
Hales et al. (18) have suggested the thrifty phenotype
hypothesis, which postulated that malnutrition (especially
the deficiency of protein) during the embryonic and infant
period causes impairment in the development of the endo-
crine pancreas and β -cell insulin secretion. Subjects were prone
to develop diabetes if they developed insulin resistance due
to abdominal obesity in the adult period. The incidence of
diabetes has increased in Korea, as the number of patients
with abdominal obesity increases, due to rapid economical
development, improved food standards as well as increased
alcohol consumption, overeating, and sedentary lifestyles.
Such developments support the thrifty phenotype hypothe-
sis. Further studies regarding the effect of environmental
factors on insulin resistance and insulin secretion are needed
to elucidate the pathogenesis of T2DM in Korea.
In our study, insulin resistance was measured by the short
insulin tolerance test. The euglycemic-hyperinsulinemic clamp
is the standard technique for evaluation of insulin sensitivi-
ty in humans (19), but its complexity limits its use in clini-
cal practice. Alternatively, the short insulin tolerance test
represents a simple and inexpensive approach for the evalua-
tion of in vivo insulin sensitivity in humans (20). It has been
validated against the clamp and is largely used in clinical
studies (21). Subjects with less than 2.5%/min of ISI were
considered to have insulin resistance, according to the find-
ings of a previous study, which was performed to evaluate
the validity of short insulin tolerance test and to investigate
the cut-off value of insulin resistance in Koreans by compar-
ing to the euglycemic clamp test (22).
It is known that the characteristic features of dyslipidemia
in metabolic syndrome are an increased level of TG and a
decreased level of HDL-cholesterol, with little change in the
levels of total cholesterol and LDL-cholesterol (4, 23). In this
study, there was no difference in total cholesterol, but a sig-
nificant difference in TG and HDL-cholesterol between the
insulin-resistance groups. 
The final manifestations of metabolic syndrome are coro-
nary heart disease, cerebrovascular disease, and peripheral
artery disease due to atherosclerosis. The concept of cardio-
vascular risk factors arose from the Framingham Heart Study,
a landmark study in cardiovascular disease epidemiology that
established older age, male sex, diabetes, hypertension, dys-
lipidemia, and smoking as the major risk factors for coronary
heart disease (24). Carotid IMT was closely associated with
coronary artery disease and cerebrovascular disease (25), and
has been proved to be a marker of generalized atherosclerosis.
It is already known that an inverse relationship exists between
the ABPI and cardiovascular diseases (26) and that the ABPI
can be a marker for generalized atherosclerotic disease (27).
CAC, a marker of atherosclerosis, can be quantified non-inva-
sively and accurately by EBT (28). A direct relationship exists
between CAC and both histological and in vivo intravascu-
lar ultrasound measures of atherosclerotic plaque. CAC pre-
dicts future CAD end points in asymptomatic and symp-
tomatic adults, while CAC quantity is an independent pre-
dictor of angiographically defined CAD after controlling for
established CAD risk factors (29). Many established CAD
risk factors, such as male sex, older age, smoking, abnormal
lipid levels, and high blood pressure are related to CAC quan-
tity (30). In this study, there were no differences in IMT,
ABPI, or CAC levels between the NW and OW groups, but
a significant difference in IMT was found according to abdom-
inal obesity. Furthermore, ABPI as a valid index of atheroscle-
rosis was lower and CAC score was higher in patients with
abdominal obesity than those without abdominal obesity.
BMI is useful, albeit crude, population-level measure of
overweightness and overall obesity (31, 32). Body weight
and height are simple to measure and have been widely includ-
ed in clinical and population health surveys. However, BMI
does not distinguish between the weight of fat and muscles
or body frame. Moreover, abdominal fat mass can vary con-
siderably within a narrow range of total body fat or BMI,
and WHR and waist circumference provide additional infor-
mation on the nature of obesity. These anthropometric mea-
sures have been associated with abdominal fat mass as mea-
sured by computed tomography or magnetic resonance imag-
ing (32) and are economically and easily obtained. Thus,
WHR and waist circumference have been recommended for
the assessment of abdominal obesity in population-based
studies (32). In many population studies, however, abdomi-
nal obesity has not been assessed or has been measured by
the participants themselves. Furthermore, there is a lack of
consistency in the selection and cut-off points for the anthro-
pometric indicators of abdominal obesity (31, 33). 
The present study indicates that abdominal obesity is asso-
ciated with atherosclerosis in T2DM patients and appears toprovide additional information beyond BMI in predicting
atherosclerosis. Therefore it is important to control abdomi-
nal obesity and insulin resistance in T2DM patients.
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